Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency

Area of Science:

• Pediatric Hematology
• Immunology
• Transplantation Medicine

Background:

• Primary immunodeficiencies (PID) are a significant cause of mortality in children.
• Hematopoietic stem cell transplantation (HSCT) is the primary treatment for many PID.
• Umbilical cord stem cells offer an alternative HSC source, but data on UCSCT for PID is limited.

Purpose of the Study:

• To evaluate the outcomes of umbilical cord stem cell transplantation (UCSCT) in pediatric patients with primary immunodeficiencies (PID).
• To assess graft-versus-host disease (GvHD) and immune reconstitution following UCSCT for PID.
• To report single-center experience with UCSCT for PID.

Main Methods:

• Retrospective analysis of 14 patients (15 UCSCTs) with PID treated at a single center.
• Patients included severe combined immunodeficiency (SCID) and other combined immunodeficiencies.
• Data collected on engraftment, GvHD, immune reconstitution, and survival.

Main Results:

• All patients achieved engraftment, with median neutrophil engraftment at 22 days and platelet engraftment at 51 days.
• One patient experienced Grade III graft-versus-host disease (GvHD).
• Full donor T-cell chimerism was observed in 11 patients, B-cell chimerism in six. Six of nine patients showed normal IgG levels and vaccine responses after one year.

Conclusions:

• Umbilical cord stem cell transplantation (UCSCT) demonstrates successful engraftment and immune reconstitution in PID patients.
• UCSCT is a feasible and effective treatment option for children with primary immunodeficiencies.
• Consideration of UCSCT for PID patients requiring stem cell therapy is recommended.